Bristol Myers Squibb Co Institutional Investor Sentiment Worsened in Q2 2019

Bristol-Myers Squibb Company (NYSE:BMY) Logo

Sentiment for Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) institutional sentiment decreased to 1.04 in 2019 Q2. Its down -0.04, from 1.08 in 2019Q1. The ratio fall, as 580 active investment managers started new or increased positions, while 557 cut down and sold their stock positions in Bristol Myers Squibb Co. The active investment managers in our partner’s database now have: 1.25 billion shares, up from 1.21 billion shares in 2019Q1. Also, the number of active investment managers holding Bristol Myers Squibb Co in their top 10 positions decreased from 24 to 21 for a decrease of 3. Sold All: 90 Reduced: 467 Increased: 460 New Position: 120.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $80.92 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 13.03 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

The stock decreased 0.28% or $0.14 during the last trading session, reaching $49.47. About 6.18 million shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 24.64% since September 13, 2018 and is downtrending. It has underperformed by 24.64% the S&P500.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on October, 24. They expect $1.05 earnings per share, down 3.67 % or $0.04 from last year’s $1.09 per share. BMY’s profit will be $1.72 billion for 11.78 P/E if the $1.05 EPS becomes a reality. After $1.18 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -11.02 % negative EPS growth.

Sector Gamma As holds 9.85% of its portfolio in Bristol-Myers Squibb Company for 1.35 million shares. Terril Brothers Inc. owns 464,354 shares or 6.72% of their US portfolio. Moreover, Sphera Funds Management Ltd. has 5.77% invested in the company for 929,900 shares. The Massachusetts-based Baupost Group Llc Ma has invested 5.34% in the stock. Kamunting Street Capital Management L.P., a Connecticut-based fund reported 110,436 shares.

Since January 1, 0001, it had 2 insider purchases, and 0 insider sales for $728,360 activity.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Ratings analysis reveals 60% of Bristol Myers’s analysts are positive. Out of 5 Wall Street analysts rating Bristol Myers, 3 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $4900 while the high is $63. The stock’s average target of $54.40 is 9.97% above today’s ($49.47) share price. BMY was included in 12 notes of analysts from March 20, 2019. Bank of America maintained it with “Neutral” rating and $4900 target in Tuesday, September 3 report. On Wednesday, April 17 the stock rating was maintained by BMO Capital Markets with “Outperform”. Barclays Capital upgraded the stock to “Overweight” rating in Friday, May 3 report. As per Thursday, June 13, the company rating was maintained by UBS. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Buy” rating given on Wednesday, March 20 by BMO Capital Markets.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: which released: “Stock Market Today: Biotech in Focus, Trade Talks Steady Stocks – Yahoo Finance” on August 26, 2019, also with their article: “Seth Klarman Buys XPO Logistics, Exits 3 Positions in 2nd Quarter – Yahoo Finance” published on August 14, 2019, published: “Can Eliquis Continue To Add $1 Billion In Annual Sales For Bristol-Myers Squibb? – Forbes” on August 23, 2019. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: and their article: “Hedge Funds Have Never Been This Bullish On Bristol Myers Squibb Company (BMY) – Yahoo Finance” published on June 05, 2019 as well as‘s news article titled: “Do Institutions Own Bristol-Myers Squibb Company (NYSE:BMY) Shares? – Yahoo Finance” with publication date: August 05, 2019.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.